WEIGHT-BASED DOSING OF ENOXAPARIN AND ANTIFACTOR XA LEVELS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN MEDICALLY-ILL PATIENTS

SOURIS K; SWATHI B; ENP SAINATH; LAHARI V

doi:10.22159/ajpcr.2022.v15i5.44649

Authors

SOURIS K Department of Pharmacology, Osmania Medical College, Hyderabad Telangana, India. https://orcid.org/0000-0002-8757-9689
SWATHI B Department of Pharmacology, Osmania Medical College, Hyderabad Telangana, India.
ENP SAINATH Department of Pharmacology, Osmania Medical College, Hyderabad Telangana, India. https://orcid.org/0000-0002-8757-9689
LAHARI V Department of Pharmacology, Government Medical College (Rims), Ongole, Andhra Pradesh, India

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i5.44649

Keywords:

Antifactor Xa, Anticoagulation, Enoxaparin, Low-weight, Thromboprophylaxis, Venous thromboembolism

Abstract

Objective: The objective of the study was to evaluate peak antifactor Xa (aFXa) levels in low-weight patients receiving enoxaparin for VTE prophylaxis.

Methods: Retrospective cohort of adult patients weighing <55 kg who was hospitalized at tertiary care Center between January 2019 through February 2020. All patients received enoxaparin for VTE prophylaxis with a peak aFXa level drawn. The primary end point was the proportion of patients achieving peak aFXa levels within the goal range of 0.2–0.5 units/ml.

Results: Of 65 patients receiving enoxaparin for VTE prophylaxis with an appropriately timed peak aFXa level, 74% achieved goal peak aFXa levels and the median daily dose of enoxaparin was 30 mg. The mean weight was about 44 kg. No significant correlations between aFXa level and body mass index or body weight were found.

Conclusion: A lower dose of enoxaparin may be reasonable in low-weight patients for VTE prophylaxis. There appears to be no safety concerns with reduced enoxaparin dosing in low-weight patients. More robust data are needed to confirm these findings.

Downloads

Download data is not yet available.

References

Centers of Medicare & Medicaid Services. Clinical Quality Measures Finalized for Eligible Hospitals and Critical Access Hospitals Beginning with FY. Baltimore: United States Department of Health and Human Services; 2014.

Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2016;141 2 Suppl: e195S-6S.

???. Lovenox (Enoxaparin) [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis; 2017.

Ludwig KP, Simons HJ, Mone M, Barton RG, Kimball EJ. Implementation of enoxaparin protocol forvenous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother. 2017;45:1356-62.

Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2016;141 2 Suppl: e24S-43S.

Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 2010;29:233-40. doi: 10.1007/ s11239-009-0418-z, PMID 19902146.

Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S. doi: 10.1378/chest.119.1_ suppl.64s, PMID 11157643.

Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically ill patients. Thromb Res 2010;125:220-3. doi: 10.1016/j.thromres.2009.02.003, PMID 19272635.

Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012;87:740-3.

Jiménez D, Díaz G, Iglesias A, César J, García-Avello A, Martí D, et al. Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass. Arch Bronconeumol 2008;44:660-3. PMID 19091234.

Egan G, Ensom MH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: A critical review. Can J Hosp Pharm 2015;68:33-47. doi: 10.4212/cjhp.v68i1.1423, PMID 25762818.

Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: Literature review and dosing recommendations. Ann Pharmacother 2018;52:898-909. doi: 10.1177/1060028018768449, PMID 29592538.